Non-Alcoholic Steatohepatitis Biomarkers Market Industry Analysis Covering Trends, Drivers, And Future Outlook
The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Will Be The Estimated Market Size Of The Non-Alcoholic Steatohepatitis Biomarkers Market By 2030?
The non-alcoholic steatohepatitis biomarkers market size has experienced significant expansion in recent years. Projections indicate it will grow from $1.68 billion in 2025 to $2.08 billion in 2026, achieving a compound annual growth rate (CAGR) of 23.2%. Historically, this growth can be attributed to the increasing prevalence of metabolic disorders, the rising incidence of obesity and type 2 diabetes, the expansion of liver disease research programs, the availability of advanced diagnostic assays, and growing pharmaceutical interest in nash therapies.
The non-alcoholic steatohepatitis biomarkers market size is anticipated to undergo significant expansion in the upcoming years. Its valuation is predicted to reach $4.6 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 22.0%. This growth during the forecast period is primarily driven by escalating investments in precision hepatology, a heightened demand for non-invasive diagnostic instruments, the broadening of biomarker-driven clinical trials, the increasing implementation of personalized medicine strategies, and a stronger emphasis on managing diseases at their initial stages. Prominent trends expected throughout this period include the accelerated creation of non-invasive diagnostic biomarkers, the increasing utilization of serum-based NASH biomarkers, the expanding integration of artificial intelligence in biomarker analysis, the wider application of companion diagnostics in pharmaceutical development, and an enhanced focus on identifying diseases early.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9002&type=smp
What Market Drivers Are Helping Shape The Non-Alcoholic Steatohepatitis Biomarkers Market Expansion?
The increasing incidence of liver cancer is set to boost the expansion of the non-alcoholic steatohepatitis biomarkers market in the future. Liver cancer involves the formation of malignant growths within the liver, originating either within the organ itself (primary liver cancer) or spreading to it from other bodily regions (secondary or metastatic liver cancer). Non-alcoholic steatohepatitis (NASH) biomarkers find application in liver cancer for purposes such as early identification, tracking disease advancement, evaluating treatment efficacy, offering prognostic insights, and potentially lessening the requirement for invasive medical interventions. For example, reports from July 2025 by ecancer medical science, a UK-based cancer journal, previously forecasted that new cases of liver cancer are projected to nearly double from 870,000 in 2022 to 1.52 million by 2050. This surge is primarily attributed to population growth and aging, with Africa expected to experience the sharpest increases. Furthermore, liver cancer fatalities are also predicted to rise from 760,000 in 2022 to 1.37 million by 2050. Consequently, the increasing prevalence of liver cancer is a key factor propelling the expansion of the non-alcoholic steatohepatitis biomarkers market.
How Is The Non-Alcoholic Steatohepatitis Biomarkers Market Distributed Across Key Segments?
The non-alcoholic steatohepatitis biomarkers market covered in this report is segmented –
1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types
2) By Technology: Enzyme-Linked Immunosorbent Assay (ELISA), Mass Spectrometry, Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Other Technologies
3) By End Use: Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses
Subsegments:
1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid, Procollagen III N-terminal Propeptide (PIIINP), Fibrosis-4 (FIB-4) Index
2) By Serum Biomarkers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Adiponectin
3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA), 8-Isoprostane, Advanced Oxidation Protein Products (AOPP)
4) By Apoptosis Biomarkers: Caspase-3, Cytochrome c, Liver Inhibitory Protein (LIP)
5) By Other Types: Metabolomic Biomarkers, Genetic Biomarkers, Inflammatory Biomarkers
Which Trends Are Affecting The Non-Alcoholic Steatohepatitis Biomarkers Market Framework?
Leading firms within the non-alcoholic steatohepatitis biomarkers market are integrating sophisticated biomarker-platform technologies, including multi-analyte fibrosis-scoring assays, to improve non-invasive disease evaluation and patient risk categorization. Such assays analyze several fibrosis-related proteins from a sole blood sample and employ an algorithm to produce a numerical result, thereby facilitating prognostic assessment and aiding in the detection of advanced fibrosis. As an illustration, in July 2023, Siemens Healthineers, a medical-technology enterprise based in Germany, obtained breakthrough device status from the US Food and Drug Administration for its Enhanced Liver Fibrosis Test. This particular test, a multi-analyte fibrosis-scoring assay, is designed to assist in identifying advanced fibrosis and cirrhosis in individuals diagnosed with non-alcoholic fatty liver disease, providing a numerical score derived from three direct fibrosis biomarkers. This test assists in the earlier clinical assessment of liver disease severity and lessens the need for invasive biopsy procedures.
Which Companies Form The Competitive Landscape Of The Non-Alcoholic Steatohepatitis Biomarkers Market?
Major companies operating in the non-alcoholic steatohepatitis biomarkers market are Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Immuron Ltd, Metacrine
Access The Complete Non-Alcoholic Steatohepatitis Biomarkers Market Report:
Which Region Commands The Largest Share Of The Non-Alcoholic Steatohepatitis Biomarkers Market?
North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Non-Alcoholic Steatohepatitis Biomarkers Market Report for Deeper Competitive Insights
Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis Biomarkers Market 2026, By The Business Research Company
Non Alcoholic Steatohepatitis Treatment Market Report 2026
Non Alcoholic Steatohepatitis Treatment Market Report 2026
Fatty Liver Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
